

## REVIEW

### Achintya D. Singh, MD, MBBS

Department of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH

### Simon R. Mucha, MD

Department of Critical Care Medicine, Respiratory Institute, Cleveland Clinic; Clinical Instructor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

### Christina C. Lindenmeyer, MD

Co-director, Cleveland Clinic Medical Intensive Liver Unit, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH; Associate Director of Basic Science Education, and Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

# Cirrhotic coagulopathy: A rebalanced hemostasis

## ABSTRACT

Cirrhosis has been regarded as a hypocoagulable state associated with an increased risk of bleeding. But patients with cirrhosis also have a high incidence of thrombotic complications, challenging this dogma. We now recognize that in cirrhosis there is a simultaneous decrease in both clotting and anticlotting factors, leading to a new equilibrium. Conventional coagulation tests such as the platelet count and prothrombin time do not assess the reduced anticoagulation factors in cirrhosis and overestimate the bleeding risk, and any intervention based on these test results can lead to thrombotic complications. This article reviews the changes in hemostasis associated with cirrhosis, newer tests for assessing coagulation, and preprocedural minimization of coagulopathy.

## KEY POINTS

The rebalanced hemostasis of cirrhosis is a delicate equilibrium of antithrombotic and prothrombotic changes associated with decreased synthetic liver function, inflammation, and endothelial and platelet activation related to cirrhosis.

There is no evidence to support routine transfusion of blood products to "correct" coagulopathy before low-risk procedures, since this does not decrease procedure-specific bleeding risk and is itself associated with significant risk.


Viscoelastic tests such as thromboelastography may better reflect the true state of cirrhotic hemostasis, but further studies are needed to establish validated transfusion thresholds.

**C**OAGULOPATHY—CHARACTERIZED BY prolonged prothrombin time, elevated international normalized ratio (INR) of the prothrombin time, prolonged activated partial thromboplastin time, low fibrinogen levels, and low platelet counts—is a hallmark of advanced cirrhosis. Traditionally, cirrhosis has been considered a hypocoagulable state in which the risk of life-threatening bleeding complications is increased.<sup>1-3</sup>

Evidence of this comes from the PRO-LIVER study,<sup>4</sup> which prospectively followed 280 patients with cirrhosis for a median of 1,129 days. Significant bleeding events occurred in 5.45% of patients per year.<sup>4</sup> The bleeding rate is higher in patients with advanced liver disease who need to be admitted to the hospital because of acute decompensation of their liver disease, or for patients with cirrhosis who need to be admitted to the intensive care unit for any reason.<sup>3,5</sup> Most of these bleeding events are gastrointestinal and most are thought to be related to elevated portal pressures.<sup>4,5</sup> Importantly, markers of coagulopathy such as elevated INR, thrombocytopenia, and low fibrinogen levels have not been shown to correlate with or predict the risk of bleeding events accurately.<sup>6</sup>

However, patients with cirrhosis also have a high incidence of thrombotic complications such as portal vein thrombosis and venous thromboembolism, which are independently associated with significant morbidity, acute hepatic decompensation, and death.<sup>7,8</sup> The incidence of portal vein thrombosis in patients with cirrhosis has varied widely in different studies, owing to differences in the populations studied, but it is higher than in patients

doi:10.3949/cjcm.89a.21018



**Figure 1.** Coagulation and anticoagulation in patients with cirrhosis are rebalanced due to simultaneous decreases in clotting and anticlotting pathways. However, this balance is dynamic, and concomitant conditions such as infection and acute kidney injury can tip the balance, resulting in a clotting or bleeding complication. (ADAMTS13 = a disintegrin and metalloproteinase with thrombospondin type 1 motifs, member 13)

without cirrhosis.<sup>9,10</sup> A rate ranging between 3.2% and 4.1% at 1 year after diagnosis is often cited and increases over time.<sup>11,12</sup>

In a large case-control study, the relative risk of venous thromboembolism in patients with cirrhosis was found to be 1.74 (95% confidence interval [CI] 1.54–1.95) compared with patients without liver disease.<sup>13</sup> These findings were echoed by data from the Multiple Environmental and Genetic Assessment study,<sup>14</sup> which showed that in hospitalized patients, liver disease was associated with significantly increased risk of venous thromboembolism (adjusted odds ratio [OR] 1.7, 95% CI 1.0–2.9).<sup>14</sup>

This increased risk of thrombotic events chal-


lenges the notion that patients with cirrhosis are “autoanticoagulated” and highlights the need for a more nuanced evaluation of the coagulopathy of cirrhosis.

In fact, the liver synthesizes most proteins of the coagulation system. Cirrhosis results in a simultaneous decrease in both procoagulant and anticoagulant factors, resulting in a delicate state of rebalanced hemostasis,<sup>15</sup> metaphorically illustrated in **Figure 1**. This coagulation profile is unique to the individual patient and is influenced by the etiology of liver disease, disease severity, acute illnesses, and ongoing therapy.<sup>16,17</sup> Conventional coagulation tests such as prothrombin time, INR, and platelet count measure procoagulant

## 1. Platelet activation

## 2. Coagulation

## 3. Fibrinolysis



**Figure 2.** The 3 phases of coagulation, involving a range of clotting factors (as Roman numerals).

HK = high-molecular-weight kinogen; tPA = tissue plasminogen activator; uPA = urokinase plasminogen activator

factors but not the anticoagulation factors, and therefore they are inadequate to accurately assess bleeding risk and guide management.<sup>2,11</sup>

The purpose of this review is to elucidate the current understanding of coagulopathy of cirrhosis, how to assess it, and how to manage bleeding risk in patients about to undergo invasive procedures.

## ■ PATHOPHYSIOLOGY OF HEMOSTASIS

The normal hemostatic process comprises 3 phases (Figure 2):

- Platelet activation: When the vessel wall is injured, subendothelial collagen and tissue factor are exposed, triggering platelet activation and primary hemostasis with adhesion of the initial platelet plug through interactions with von Willebrand factor, factor VIII, glycoprotein IIb/IIIa receptors, and fibrinogen.
- Coagulation: Sequential activation of prothrombotic coagulation factors leads to thrombin activation, thrombus formation, and thrombus stabilization through conversion of fibrinogen to fibrin

and cross-linking of fibrin polymers.

- Fibrinolysis or clot dissolution.

Cirrhosis affects all 3 phases, leading to a delicate new equilibrium—the rebalanced hemostasis of cirrhosis. This new balance is easily disturbed and tipped toward either bleeding or thrombosis by acute events such as infection, renal failure, and invasive procedures with or without prophylactic transfusions.

## A new balance in platelet activation

**Fewer platelets.** Thrombocytopenia is common in cirrhosis and portal hypertension, likely due to increased platelet destruction, reduced hepatic synthesis of thrombopoietin, and increased splenic aggregation (which further increases thrombopoietin clearance).<sup>18</sup> Tripodi et al<sup>19</sup> found that platelet counts as low as  $60 \times 10^9/L$  in plasma from patients with cirrhosis were still sufficient to yield in vitro thrombin generation similar to that in plasma from healthy controls with normal platelet counts. This highlights the importance of qualitative alterations in platelet activation beyond the quantitative decrease in platelet counts in cirrhosis.

**More von Willebrand factor.** In contrast to the coagulation factors synthesized by the liver, von Willebrand factor is produced, stored, and released by the vascular endothelium. Its levels are preserved or even increased in cirrhosis.<sup>20</sup> Levels of von Willebrand factor have also been shown to progressively increase with more advanced liver disease. Lisman et al<sup>20</sup> reported that, compared with healthy controls, patients with Child-Pugh class A cirrhosis had von Willebrand factor antigen levels 380% higher, those with class B cirrhosis had levels 500% higher, and those with class C cirrhosis had levels 760% higher. Similarly, von Willebrand factor levels were 790% higher in patients with acute liver failure.<sup>20</sup>

**Less ADAMTS13.** ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motifs, member 13) is a potent inhibitor of von Willebrand factor and is reduced in cirrhosis.<sup>21</sup> However, data are conflicting as to the magnitude of this decrease and its correlation with disease severity, perhaps partly because ADAMTS13 is difficult to measure and results vary with different assays.<sup>19</sup>

Thus, the data suggest that in patients with cirrhosis, thrombocytopenia is countered by a simultaneous increase in von Willebrand factor and a decrease in ADAMTS13, resulting in only mildly decreased or even increased platelet activity. Indeed, the excess risk of thrombosis observed in patients with biliary cirrhosis has been attributed to platelet activation.<sup>22</sup>

### Rebalanced coagulation vs anticoagulation

The coagulation cascade is driven by procoagulant factors and inhibited by anticoagulant factors.<sup>23,24</sup> As both types of factors are predominantly produced in the liver, this phase is rebalanced in cirrhosis.

**Procoagulation factors are decreased.** Release of tissue factor from the endothelium activates factor VII, forming the tissue factor-VIIa complex, which leads to activation of factors V, IX, and X and ultimately to conversion of prothrombin to thrombin. As all coagulation factors except for factor VIII (produced in hepatic sinusoidal endothelial cells) are synthesized in hepatocytes, conventional coagulation tests that assess procoagulant factors tend to suggest a hypocoagulable state in conditions of hepatic synthetic dysfunction such as cirrhosis or liver failure: eg, the prothrombin time will be prolonged and the INR will be high.

**Anticoagulation factors are also decreased.** Anticoagulation factors, in contrast, exert their effect in the endothelium and are difficult to quantify *in vitro*.<sup>25</sup> For example, tissue factor pathway inhibitor forms a complex with activated factor X. It inhibits the tissue

factor-factor VIIa complex and facilitates degradation of factors V and VIIIa. Tissue factor pathway inhibitor has been shown to be reduced in cirrhosis.

Moreover, the key anticoagulant proteins activated protein C and protein S have been similarly shown to be reduced in cirrhosis. Activated protein C with protein S as a cofactor inhibits activated factors V and VII and thus thrombin formation. The activity of protein C is regulated in the endothelium by thrombomodulin, and “thrombomodulin resistance” has been demonstrated in plasma from patients with cirrhosis.<sup>26,27</sup> This affirms the hypercoagulable effect of decreased hepatic synthesis of proteins C and S *in vitro*.

In fact, the thrombin generation potential in plasma from cirrhotic patients has been demonstrated to be similar to that of noncirrhotic patients, confirming the rebalanced state of hemostasis in cirrhosis.<sup>19</sup>


### Decreased fibrinolysis

Plasmin-mediated fibrinolysis and clot dissolution is the final step in hemostasis. Plasmin is activated from plasminogen by fibrin, as well as by tissue plasminogen activator, urokinase plasminogen activator, and activated factor XII. Conversion of plasminogen to plasmin is inhibited by thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor.<sup>15,28</sup> A decrease in the plasmin activation pathway results in a hypofibrinolytic state, while an increase results in a hyperfibrinolytic state.

Cirrhosis has been shown to be associated with both quantitative and qualitative changes in the fibrinolytic pathway. Plasminogen levels are reduced in patients with cirrhosis, likely due to the combined effects of decreased production and increased consumption related to the frequent activation of the coagulation cascade from ongoing inflammation.<sup>24</sup> Oxidative stress, leading to modifications of fibrin, and increased sialic acid content and altered calcium binding lead to decreased clot permeability and impaired fibrinolysis.<sup>29,30</sup> Together these qualitative and quantitative changes result in a net decrease in fibrinolysis in cirrhosis.

### Inflammation and infection can tip the balance

Systemic inflammation is an important factor in the development and progression of chronic liver disease, acute liver failure, and acute-on-chronic liver failure. Moreover, patients with liver disease are at increased risk of both primary and secondary infections, which in turn contribute to disease progression.<sup>31–33</sup>



Parameters	Description	Normal range	Interpretation
R time	Latent time from test initiation to initial clot formation and is approximately equal to the rate of thrombin formation	15–23 minutes (whole blood) 5–10 minutes (kaolin added)	Prolongation shows deficiency or inhibition of clotting factors (anticoagulants or autoimmune inhibitors)
Alpha angle	Measures rate of clot progression Determined by fibrin sheath buildup and cross-linking	22–38 degrees (whole blood) 53–67 degrees (kaolin added)	Narrow or reduced angle suggests deficiency of fibrinogen or its decreased activity Low platelets counts or dysfunction in conditions like uremia, cirrhosis can also decrease the angle
K time	Time required to achieve a particular clot strength, ie, 20-mm amplitude	5–10 minutes (whole blood) 1–3 minutes (kaolin added)	Prolonged in fibrinogen deficiency or decreased function
Maximum amplitude (MA)	Ultimate strength of the platelet clot	47–88 mm (whole blood) 59–68 mm (kaolin added)	Low indicates low platelet number or function or decreased fibrinogen levels or function; can also be affected by other factors such as factor XIII deficiency
Coagulation index	Composite indicator of the coagulation profile	–3 to 3	Increased in hypercoagulable states, decreased in hypocoagulable states
Clot lysis at 30 minutes (LY)	Percentage decrease in amplitude 30 minutes after MA; indicates fibrinolysis	0–7.5%	Decreased in hypercoagulable states, increased in hyperfibrinolytic states

**Figure 3.** Thromboelastography is a promising test of coagulation. The horizontal axis represents time, the vertical axis represents deflection of the thromboelastography probe. The R time is also assessed by tests such as the prothrombin time (PT), the activated partial thromboplastin time (aPTT), and the activated clotting time (ACT). D-dimer is used to assess fibrinolysis.

Adapted from Singh AD, Shalimar. Use of blood products and drugs before procedures in patients with cirrhosis. *Clin Liver Dis (Hoboken)* 2020; 16(4):153–157. doi:10.1002/cld.906, reference 36.

Several mechanisms link inflammation and coagulopathy. Inflammatory cytokines lead to direct activation of platelets and the endothelium, and endothelial activation in turn prompts the release of tissue factor and von Willebrand factor. Tissue factor activates the extrinsic coagulation cascade, and increasing levels of von Willebrand factor further promote platelet activation and adhesion. Increased levels of fibrinogen, an acute-phase reactant, can tip the balance toward a more hypercoagulable state. Similarly, inflammation-induced expression of plasminogen activator inhibitor 1 further inhibits fibrinolysis. Eventually, prolonged activation of a systemic inflammatory response can result in exhaustion of thrombotic and thrombolytic systems, leading to a state of consumptive coagulopathy.<sup>34</sup>

These mechanisms highlight the complexity of coagulopathy of advanced liver disease and emphasize the importance of individualized assessment and management of coagulopathy in patients with cirrhosis and liver failure, particularly in patients with systemic inflammation or sepsis, or both.

### ASSESSING CLOTTING AND ANTICLOTTING IN CIRRHOSIS

An accurate assessment of the coagulation system is paramount in the clinical management of cirrhosis. An ideal test should evaluate both the clotting and the anticlotting pathways to provide an accurate assessment of hemostasis to guide therapy.

#### Conventional tests assess only clotting and may overestimate bleeding risk

The conventional tests for assessing coagulation are the prothrombin time, INR, platelet count, and fibrinogen level. These tests cannot assess the impact of the anticoagulant mechanisms outlined above<sup>2</sup> and may overestimate the bleeding risk in cirrhosis. Prolongation of the prothrombin time and activated partial thromboplastin time indicates a decrease in hepatic synthesis of procoagulation factors and correlates with hepatic function, but this does not adequately quantify bleeding risk.

Of importance is that the INR is standardized and validated using plasma from patients receiving vitamin K antagonists such as warfarin. There is no standard reference plasma that could be used in clinical practice to express a normalized ratio of the prothrombin time for patients with cirrhosis.<sup>15</sup>

Similarly, the quantitative decrease of platelet counts and fibrinogen levels in cirrhosis is balanced by qualitative changes in platelet activation and

fibrinolysis, making the absolute values difficult to interpret in the context of the rebalanced state of hemostasis.

#### Viscoelastic tests are promising but need more study

Viscoelastic tests such as thromboelastography and rotational thromboelastometry provide a holistic evaluation of the coagulation process, assessing clot formation, clot propagation, maximum clot strength, and fibrinolysis as a reflection of shear stress *in vitro*. Viscoelastic tests are performed using whole blood, assessing coagulation in a more global, functional, and potentially clinically relevant fashion than individual coagulation parameters.

Thromboelastography is performed with a torsion pin suspended in an oscillating cup containing whole blood.<sup>35</sup> As the blood begins to clot, the initial platelet clot and fibrin strands move this pin. The deflection of the pin is proportional to clot strength and is displayed graphically (**Figure 3**).<sup>36</sup> The pattern is altered in patients with abnormal hemostasis (**Figure 4**).


Rotational thromboelastometry uses a stationary cup, a rotating pin, and optical methods to measure clot formation instead of the shearing forces used by thromboelastography. It is considered less vulnerable to movement and vibration.<sup>37,38</sup>

Viscoelastic tests were developed as point-of-care tests to provide rapid results during surgery or in the trauma bay—in 15 to 20 minutes, compared with conventional tests, which require significantly longer turnaround times (eg, 45–60 minutes for prothrombin time and INR).

Viscoelastic testing is well established in trauma care and cardiothoracic surgery, where its use has significantly reduced blood product utilization and has led to improved outcomes.<sup>39</sup> It has been shown to predict the need for massive transfusions during liver transplant, and transfusion protocols guided by viscoelastic testing during liver transplant surgery have been shown to reduce the intraoperative use of blood products without an associated increased rate of bleeding.<sup>40,41</sup>

Outside the operating room, a small study by Chau et al<sup>42</sup> found that abnormal results on thromboelastography were associated with risk of rebleeding in patients with esophageal variceal hemorrhages, but data on predicting spontaneous bleeding risk remain limited.

Thromboelastography is highly reproducible and routinely shows normal coagulation profiles in patients with cirrhosis in stable condition.<sup>43</sup> For example, in 273 patients with compensated cirrhosis, Stravitz<sup>44</sup>

Tracing	Pattern
	<b>Normal</b> R time, K time and alpha angle normal
	<b>Anticoagulant use or hemophilia</b> (factor deficiency) R time and K time prolonged Maximum amplitude, alpha angle decreased
	<b>Use of platelet blockers</b> (thrombocytopenia, thrombocytopathy) R time normal, K time prolonged Maximum amplitude decreased
	<b>Use of fibrinolytic drugs</b> (urokinase, streptokinase, tissue plasminogen activator) R time normal Maximum amplitude shows continuous decrease Clot lysis at 30 minutes > 7.5% Clot lysis at 60 minutes > 15.0%
	<b>Hypercoagulation</b> R time and K time decreased Maximum amplitude and alpha angle increased
	<b>Disseminated intravascular coagulation</b>  Stage 1: Hypercoagulable state with secondary fibrinolysis  Stage 2: Hypocoagulable state

**Figure 4.** Results of thromboelastography in various conditions.

found that the thromboelastography parameters were within the normal range, even though the prothrombin time and INR were prolonged. Similarly, only 14 (27%) of 51 patients with stable cirrhosis had abnormal clotting times on rotational thromboelastography

in a study by Tripodi et al.<sup>45</sup>

However, the coagulopathy of liver disease is dynamic, and thromboelastography displays a more hypocoagulable profile with increasing severity of liver disease as well as in the setting of acute decom-

**TABLE 1**  
**Bleeding risk associated with invasive procedures**

**High-risk procedures**

All major surgeries (cardiac, intra-abdominal, orthopedic, brain, spine)  
Intracranial pressure catheter insertion  
Endoscopy: large polypectomy with endoscopic mucosal resection or submucosal resection

**Moderate-risk procedures**

Lumbar puncture  
Percutaneous or transjugular liver biopsy  
Transarterial or percutaneous therapies for hepatocellular carcinoma  
Transjugular intrahepatic portosystemic shunt  
Endoscopy for percutaneous gastrostomy placement, biliary sphincterotomy

**Low-risk procedures**

Paracentesis  
Thoracentesis  
Dental extraction  
Cardiac catheterization  
Central line placement  
Endoscopy for diagnosis, variceal band ligation, uncomplicated polypectomy

**Note:** Risk is calculated based on relative vascularity, expected vascular breach, and potential clinical consequences. Risk should always be defined by the clinician performing the procedure.

Adapted from Intagliata NM, Argo CK, Stine JG, et al. Concepts and controversies in haemostasis and thrombosis associated with liver disease: Proceedings of the 7th International Coagulation in Liver Disease Conference. *Thromb Haemost* 2018; 118(8):1491–1506. doi:10.1055/s-0038-1666861, reference 55.

pensation. De Pietri et al<sup>46</sup> compared the coagulation profiles of 261 patients with decompensated cirrhosis and Model for End-Stage Liver Disease scores between 15 and 40 with those of 40 healthy participants. The latency time between test initiation and clot formation (R time) was prolonged in 41.5% of the patients, and the ultimate strength of the clot (maximal amplitude) was weaker in 79.3% patients with cirrhosis.<sup>46</sup>

Further, Lloyd-Donald et al<sup>47</sup> reported that 34 critically ill patients with Child-Pugh class C cirrhosis had longer R times, weaker clot strength, and reduced clot lysis compared with 157 healthy controls. This further supports the dynamicity of liver disease and the impact of underlying cirrhosis on coagulability.

However, certain limitations restrict widespread clinical implementation of viscoelastic testing. The normal limits are not standardized, and clinical trials have used different cutoff values as indications for treatment.<sup>48–51</sup> Moreover, the impact of concomitant conditions such as sepsis or acute kidney injury on these results has not been studied.<sup>51</sup>

Accordingly, the current guidelines from the American Association for the Study of Liver Diseases<sup>11</sup> and a technical review from the American

Gastroenterology Association<sup>52</sup> state that though viscoelastic tests are promising, their clinical utility in predicting bleeding risk in patients with liver disease is yet to be firmly established. The current Society for Critical Care Medicine guidelines<sup>53</sup> recommend the use of viscoelastic testing over the conventional tests in patients with cirrhosis in the intensive care unit. The clinical applicability of these tests is detailed in the next section.

**PROPHYLACTIC OPTIMIZATION OF COAGULOPATHY**

Coagulopathy in cirrhosis is widely interpreted as a risk factor for bleeding after an invasive procedure. The need to minimize the risk of coagulopathy before procedures is a common dilemma for practitioners.

The risk of bleeding is mainly determined by the type of procedure, the clinical scenario, comorbidities, use of ultrasonographic guidance, and operator experience.<sup>54</sup> Various procedures are classified as high-, intermediate-, or low-risk (Table 1).<sup>2,55</sup>

Traditional coagulation tests do not predict post-procedural bleeding complications.<sup>56</sup> A meta-analysis

of 29 studies including 13,276 patients found that neither elevated INR (OR 1.52, 95% CI 0.99–2.33) nor thrombocytopenia (OR 1.24, 95% CI 0.55–2.77) significantly increased the risk of bleeding in patients with cirrhosis.<sup>57</sup> Moreover, the mean INR did not significantly differ between patients with bleeding complications and those without. However, there was significant heterogeneity ( $I^2 = 51\%$ ) in the pooled results, likely attributable to differences in the severity of thrombocytopenia in various studies. The risk of bleeding was associated with the type of invasive procedure, but not with the results of conventional tests of coagulopathy.<sup>57</sup>

Paracentesis, the most commonly performed procedure in patients with cirrhosis, is considered low-risk and can be done safely even if the results of conventional coagulation tests are abnormal. In a study of 1,100 therapeutic paracenteses in 628 patients, of whom 513 had cirrhosis of the liver and in whom the mean INR was 1.7, no patients received prophylactic preprocedural correction of INR, and no significant bleeding events (defined as bleeding requiring hospitalization) were reported.<sup>58</sup>

By comparison, a study of 2,740 percutaneous liver biopsies reported an increased risk of bleeding in patients with INR greater than 1.3 and platelet counts less than  $60 \times 10^9/L$ .<sup>59</sup> This area clearly needs further study.

### **Transfusion may not reduce bleeding, and it has its own risks**

Furthermore, no studies have shown that giving prophylactic transfusions of fresh frozen plasma to correct an elevated INR reduces the risk of procedure-related bleeding in patients with cirrhosis. Also, *in vitro* experiments have demonstrated that transfusion of fresh frozen plasma does not increase coagulation potential in patients with cirrhosis, as it supplies both procoagulant and anticoagulant factors in equal amounts. As a result, the increase in plasma levels of procoagulant factors may correct an elevated INR, but thrombin-generating potential does not change, or may even decrease.<sup>60,61</sup>

The current standard of practice is prejudiced toward the hypocoagulable state of coagulopathy and disregards the risks associated with blood product transfusion.<sup>36</sup> Acutely ill patients with cirrhosis are at increased risk for transfusion-related lung injury and complications from transfusion-related circulatory overload.<sup>62</sup> In a small classic study, every 100 mL of volume expansion increased the portal pressure by 1.4 cm H<sub>2</sub>O (1.03 mm Hg).<sup>63</sup> It is estimated that lowering the INR from 2.0 to 1.5 requires transfusion

of 1.5 L, which would raise the portal pressure by approximately 15.5 mm Hg.<sup>64</sup> This is important, since an elevated hepatic venous pressure gradient ( $> 12$  mm Hg) is associated with an increased risk of variceal hemorrhage.<sup>65,66</sup>

Large-volume blood product transfusions aimed at correcting an elevated INR can therefore translate to increased bleeding complications. This is supported by a recent multicenter retrospective study, which found that transfusion of fresh frozen plasma to manage acute variceal bleeding increased the risk of death within 42 days (OR 9.41, 95% CI 3.71–23.90).<sup>67</sup> Notably, patients who received fresh frozen plasma had a higher INR at baseline evaluation, and the patients who had died by 42 days had received a median of 3 units of fresh frozen plasma, compared with 0 units in those who were alive at 42 days.

Accordingly, the current recommendations advise against routine preprocedural correction of INR or thrombocytopenia in patients with cirrhosis, particularly for low-risk procedures.<sup>2,11,52,68</sup>

### **Can viscoelastic testing reduce transfusions?**

As reviewed, viscoelastic tests may more accurately assess the global coagulation status. Recent randomized controlled trials have evaluated the impact of thromboelastography-guided prophylactic transfusion protocols compared with the standard of care for the use of blood products and bleeding complications for invasive procedures and in the setting of variceal and nonvariceal gastrointestinal bleeding.<sup>48–60</sup> In all the studies, thromboelastography-guided therapy significantly reduced transfusion of blood products (fresh frozen plasma and platelets) compared with the standard of care, while the incidence of postprocedure-related bleeding between the groups was similar.

However, several limitations need to be considered when interpreting these findings. Most importantly, in these trials, the standard of care aimed to “correct” the INR and platelet counts to arbitrary near-normal thresholds. This is not in line with current restrictive recommendations for transfusion. Furthermore, transfusion thresholds in the thromboelastography-based protocols varied among trials, and there are currently no uniform and well-established transfusion thresholds for viscoelastic tests.<sup>49,50,69</sup> It remains unclear if a restrictive transfusion strategy based on viscoelastic testing is superior to a restrictive strategy based on conventional tests. The small number of patients and the very low bleeding rates observed in these trials further limit their generalizability, as they may therefore be underpowered to detect true differences between the 2 strategies.

In sum, viscoelastic tests are promising tools to both assess the coagulopathy of cirrhosis and guide preprocedural management of hemostasis, but their current use is limited by a lack of validated transfusion thresholds and limited clinical availability outside of the operating room or research setting.<sup>2</sup> Further large-scale studies are needed to establish

such thresholds to facilitate translation into general clinical practice. ■

## DISCLOSURES

Dr. Lindenmeyer has disclosed authorship for Merck Manuals. The other authors have disclosed no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

## REFERENCES

1. Tripodi A, Primignani M, Mannucci PM, Caldwell SH. Changing concepts of cirrhotic coagulopathy. *Am J Gastroenterol* 2017; 112(2):274–281. doi:10.1038/ajg.2016.498
2. O’Leary JG, Greenberg CS, Patton HM, Caldwell SH. AGA clinical practice update: coagulation in cirrhosis. *Gastroenterology* 2019; 157(1):34–43.e1. doi:10.1053/j.gastro.2019.03.070
3. Drolz A, Ferlitsch A, Fuhrmann V. Management of coagulopathy during bleeding and invasive procedures in patients with liver failure. *Visc Med* 2018; 34(4):254–258. doi:10.1159/000491106
4. Basili S, Raparelli V, Napoleone L, et al. Platelet count does not predict bleeding in cirrhotic patients: results from the PRO-LIVER study. *Am J Gastroenterol* 2018; 113(3):368–375. doi:10.1038/ajg.2017.457
5. Shah NL, Northup PG, Caldwell SH. A clinical survey of bleeding, thrombosis, and blood product use in decompensated cirrhosis patients. *Ann Hepatol* 2012; 11(5):686–690. PMID:22947530
6. Budnick IM, Davis JPE, Sundararaghavan A, et al. Transfusion with cryoprecipitate for very low fibrinogen levels does not affect bleeding or survival in critically ill cirrhosis patients. *Thromb Haemost* 2021; 121(10):1317–1325. doi:10.1055/a-1355-3716
7. Ghabril M, Agarwal S, Lacerda M, Chalasani N, Kwo P, Tector AJ. Portal vein thrombosis is a risk factor for poor early outcomes after liver transplantation: analysis of risk factors and outcomes for portal vein thrombosis in waitlisted patients. *Transplantation* 2016; 100(1):126–133. doi:10.1097/TP.0000000000000785
8. Zhang Y, Xu BY, Wang XB, et al. Prevalence and clinical significance of portal vein thrombosis in patients with cirrhosis and acute decompensation. *Clin Gastroenterol Hepatol* 2020; 18(11):2564–2572.e1. doi:10.1016/j.cgh.2020.02.037
9. Okuda K, Ohnishi K, Kimura K, et al. Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. *Gastroenterology* 1985; 89(2):279–286. doi:10.1016/0016-5085(85)90327-0
10. Nonami T, Yokoyama I, Iwatsuki S, Starzl TE. The incidence of portal vein thrombosis at liver transplantation. *Hepatology* 1992; 16(5):1195–1198. PMID:1427658
11. Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases. *Hepatology* 2021; 73(1):366–413. doi:10.1002/hep.31646
12. Ki M, Choi HY, Kim KA, Kim BH, Jang ES, Jeong SH. Incidence, prevalence and complications of Budd-Chiari syndrome in South Korea: a nationwide, population-based study. *Liver Int* 2016; 36(7):1067–1073. doi:10.1111/liv.13008
13. Søgaard KK, Horváth-Puhó E, Grønbaek H, Jepsen P, Vilstrup H, Sørensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. *Am J Gastroenterol* 2009; 104(1):96–101. doi:10.1038/ajg.2008.34
14. Ocak G, Vossen CY, Verduijn M, et al. Risk of venous thrombosis in patients with major illnesses: results from the MEGA study. *J Thromb Haemost* 2013; 11(1):116–123. doi:10.1111/jth.12043
15. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. *N Engl J Med* 2011; 365(2):147–156. doi:10.1056/NEJMra1011170
16. Stravitz RT. Thrombosis and coagulopathy in the liver transplant candidate and recipient. *Clin Liver Dis (Hoboken)* 2017; 9(1):11–17. doi:10.1002/cld.606
17. Pant A, Kopec AK, Luyendyk JP. Role of the blood coagulation cascade in hepatic fibrosis. *Am J Physiol Gastrointest Liver Physiol* 2018; 315(2):G171–G176. doi:10.1152/ajpgi.00402.2017
18. Mitchell O, Feldman DM, Diakow M, Sigal SH. The pathophysiology of thrombocytopenia in chronic liver disease. *Hepat Med* 2016; 8:39–50. doi:10.2147/HMER.S74612
19. Tripodi A, Primignani M, Chantarangkul V, et al. Thrombin generation in patients with cirrhosis: the role of platelets. *Hepatology* 2006; 44(2):440–445. doi:10.1002/hep.21266
20. Lisman T, Bongers TN, Adelmeijer J, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. *Hepatology* 2006; 44(1):53–61. doi:10.1002/hep.21231
21. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. *Blood* 2001; 98(9):2730–2735. doi:10.1182/blood.v98.9.2730
22. Vlachogiannakos J, Binas J, Siakavellas S, et al. Platelet activation and hypercoagulability in patients with early primary biliary cholangitis compared with healthy controls. *Ann Gastroenterol* 2021; 34(2):229–234. doi:10.20524/aog.2021.0572
23. Green D. Coagulation cascade. *Hemodial Int* 2006; 10(suppl 2):S2–S4. doi:10.1111/j.1542-4758.2006.00119.x
24. Zermatten MG, Fraga M, Moradpour D, et al. Hemostatic alterations in patients with cirrhosis: from primary hemostasis to fibrinolysis. *Hepatology* 2020; 71(6):2135–2148. doi:10.1002/hep.31201
25. Green D. Overview of blood coagulation. *Hemodial Int* 2001; 5(1):70–73. doi:10.1111/hdi.2001.5.1.70
26. Tripodi A, Primignani M, Chantarangkul V, et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. *Gastroenterology* 2009; 137(6):2105–2111. doi:10.1053/j.gastro.2009.08.045
27. Groeneveld D, Porte RJ, Lisman T. Thrombomodulin-modified thrombin generation testing detects a hypercoagulable state in patients with cirrhosis regardless of the exact experimental conditions. *Thromb Res* 2014; 134(3):753–756. doi:10.1016/j.thromres.2014.07.010
28. Lisman T, Leebeek FW, Mosnier LO, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. *Gastroenterology* 2001; 121(1):131–139. doi:10.1053/gast.2001.25481
29. Hugenholtz GC, Macrae F, Adelmeijer J, et al. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen. *J Thromb Haemost* 2016; 14(5):1054–1066. doi:10.1111/jth.13278
30. Narvaiza MJ, Fernández J, Cuesta B, Páramo JA, Rocha E. Role of sialic acid in acquired dysfibrinogenemia associated with liver cirrhosis. *Ric Clin Lab* 1986; 16(4):563–568. doi:10.1007/BF02886840
31. Iba T, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation. *Anesthesiology* 2020; 132(5):1238–1245. doi:10.1097/ALN.0000000000003122
32. Esmon CT. The interactions between inflammation and coagulation. *Br J Haematol* 2005; 131(4):417–430. doi:10.1111/j.1365-2141.2005.05753.x
33. Driever EG, Lisman T. Effects of Inflammation on hemostasis in acutely ill patients with liver disease. *Semin Thromb Hemost* 2022; 48(5):596–606. doi:10.1055/s-0042-1742438

34. **Blasi A, Calvo A, Prado V, et al.** Coagulation failure in patients with acute-on-chronic liver failure and decompensated cirrhosis: beyond the international normalized ratio. *Hepatology* 2018; 68(6): 2325–2337. doi:10.1002/hep.30103
35. **Thakur M, Ahmed AB.** A review of thromboelastography. *Int J Periop Ultrasound Appl Technol* 2012; 1(1):25–29. doi:10.5005/jp-journals-10027-1006
36. **Singh AD, Shalimar.** Use of blood products and drugs before procedures in patients with cirrhosis. *Clin Liver Dis (Hoboken)* 2020; 16(4):153–157. doi:10.1002/clid.906
37. **Sakai T.** Comparison between thromboelastography and thromboelastometry. *Minerva Anestesiol* 2019; 85(12):1346–1356. doi:10.23736/S0375-9393.19.13687-5
38. **Whiting D, DiNardo JA.** TEG and ROTEM: technology and clinical applications. *Am J Hematol* 2014; 89(2):228–232. doi:10.1002/ajh.23599
39. **Serraino GF, Murphy GJ.** Routine use of viscoelastic blood tests for diagnosis and treatment of coagulopathic bleeding in cardiac surgery: updated systematic review and meta-analysis. *Br J Anaesth* 2017; 118(6):823–833. doi:10.1093/bja/aex100
40. **Wang SC, Shieh JF, Chang KY, et al.** Thromboelastography-guided transfusion decreases intraoperative blood transfusion during orthotopic liver transplantation: randomized clinical trial. *Transplant Proc* 2010; 42(7):2590–2593. doi:10.1016/j.transproceed.2010.05.144
41. **Lawson PJ, Moore HB, Moore EE, et al.** Preoperative thromboelastography maximum amplitude predicts massive transfusion in liver transplantation. *J Surg Res* 2017; 220:171–175. doi:10.1016/j.jss.2017.05.115
42. **Chau TN, Chan YW, Patch D, Tokunaga S, Greenslade L, Burroughs AK.** Thrombelastographic changes and early rebleeding in cirrhotic patients with variceal bleeding. *Gut* 1998; 43(2):267–271. doi:10.1136/gut.43.2.267
43. **George G, Manatasahit W, Balasubramanian M, Navarro V.** Reproducibility of TEG parameters in stable cirrhotics. *Lab Med* 2018; 49(3):226–230. doi:10.1093/labmed/lmx041
44. **Stravitz RT.** Potential applications of thromboelastography in patients with acute and chronic liver disease. *Gastroenterol Hepatol (NY)* 2012; 8(8):513–520. PMID:23293564
45. **Tripodi A, Primignani M, Chantarangkul V, et al.** The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. *Thromb Res* 2009; 124(1): 132–136. doi:10.1016/j.thromres.2008.11.008
46. **De Pietri L, Bianchini M, Rompianesi G, Bertellini E, Begliomini B.** Thrombelastographic reference ranges for a cirrhotic patient population undergoing liver transplantation. *World J Transplant* 2016; 6(3):583–593. doi:10.5500/wjt.v6.i3.583
47. **Lloyd-Donald P, Vasudevan A, Angus P, et al.** Coagulation in acutely ill patients with severe chronic liver disease: insights from thromboelastography. *J Crit Care* 2017; 38:215–224. doi:10.1016/j.jccr.2016.10.030
48. **De Pietri L, Bianchini M, Montalti R, et al.** Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: a randomized, controlled trial. *Hepatology* 2016; 63(2):566–573. doi:10.1002/hep.28148
49. **Vuyuru SK, Singh AD, Gamanagatti SR, Rout G, Gunjan D, Shalimar.** A randomized control trial of thromboelastography-guided transfusion in cirrhosis for high-risk invasive liver-related procedures. *Dig Dis Sci* 2020; 65(7):2104–2111. doi:10.1007/s10620-019-05939-2
50. **Rout G, Shalimar, Gunjan D, et al.** Thromboelastography-guided blood product transfusion in cirrhosis patients with variceal bleeding: a randomized controlled trial. *J Clin Gastroenterol* 2020; 54(3):255–262. doi:10.1097/MCG.0000000000001214
51. **Hunt H, Stanworth S, Curry N, et al.** Thromboelastography (TEG) and rotational thromboelastometry (ROTEM) for trauma induced coagulopathy in adult trauma patients with bleeding. *Cochrane Database Syst Rev* 2015; 2015(2):CD010438. doi:10.1002/14651858.CD010438.pub2
52. **Intagliata NM, Davitkov P, Allen AM, Falck-Ytter YT, Stine JG.** AGA Technical review on coagulation in cirrhosis. *Gastroenterology* 2021; 161(5):1630–1656. doi:10.1053/j.gastro.2021.09.004
53. **Nanchal R, Subramanian R, Karvellas CJ, et al.** Guidelines for the management of adult acute and acute-on-chronic liver failure in the ICU: cardiovascular, endocrine, hematologic, pulmonary, and renal considerations. *Crit Care Med* 2020; 48(3):e173–e191. doi:10.1097/CCM.0000000000004192
54. **Schepis F, Turco L, Bianchini M, Villa E.** Prevention and management of bleeding risk related to invasive procedures in cirrhosis. *Semin Liver Dis* 2018; 38(3):215–229. doi:10.1055/s-0038-1660523
55. **Intagliata NM, Argo CK, Stine JG, et al.** Concepts and controversies in haemostasis and thrombosis associated with liver disease: proceedings of the 7th International Coagulation in Liver Disease Conference. *Thromb Haemost* 2018; 118(8):1491–1506. doi:10.1055/s-0038-1666861
56. **Janko N, Majeed A, Commins I, Kemp W, Roberts SK.** Procedural bleeding risk, rather than conventional coagulation tests, predicts procedure related bleeding in cirrhosis. *Eur J Gastroenterol Hepatol* 2022; 34(2):192–199. doi:10.1097/MEG.0000000000001948
57. **Kovalic AJ, Majeed CN, Samji NS, Thuluvath PJ, Satapathy SK.** Systematic review with meta-analysis: abnormalities in the international normalised ratio do not correlate with periprocedural bleeding events among patients with cirrhosis. *Aliment Pharmacol Ther* 2020; 52(8):1298–1310. doi:10.1111/apt.16078
58. **Grabau CM, Crago SF, Hoff LK, et al.** Performance standards for therapeutic abdominal paracentesis. *Hepatology* 2004; 40(2):484–488. doi:10.1002/hep.20317
59. **Seeff LB, Everson GT, Morgan TR, et al; the HALT-C Trial Group.** Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. *Clin Gastroenterol Hepatol* 2010; 8(10):877–883. doi:10.1016/j.cgh.2010.03.025
60. **Bernal W, Caldwell SH, Lisman T.** Nails in the coffin of fresh frozen plasma to prevent or treat bleeding in cirrhosis? *J Hepatol* 2020; 72(1):12–13. doi:10.1016/j.jhep.2019.09.024
61. **Rassi AB, d'Amico EA, Tripodi A, et al.** Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: effect on conventional coagulation tests and thrombomodulin-modified thrombin generation. *J Hepatol* 2020; 72(1):85–94. doi:10.1016/j.jhep.2019.09.008
62. **Benson AB, Austin GL, Berg M, et al.** Transfusion-related acute lung injury in ICU patients admitted with gastrointestinal bleeding. *Intensive Care Med* 2010; 36(10):1710–1717. doi:10.1007/s00134-010-1954-x
63. **Zimmon DS, Kessler RE.** The portal pressure-blood volume relationship in cirrhosis. *Gut* 1974; 15(2):99–101. doi:10.1136/gut.15.2.99
64. **Giannini EG, Stravitz RT, Caldwell SH.** Correction of hemostatic abnormalities and portal pressure variations in patients with cirrhosis. *Hepatology* 2014; 60(4):1442. doi:10.1002/hep.27029
65. **Garcia-Tsao G, Bosch J.** Varices and variceal hemorrhage in cirrhosis: a new view of an old problem. *Clin Gastroenterol Hepatol* 2015; 13(12):2109–2117. doi:10.1016/j.cgh.2015.07.012
66. **Kim JN, Sohn KM, Kim MY, et al.** Relationship between the hepatic venous pressure gradient and first variceal hemorrhage in patients with cirrhosis: a multicenter retrospective study in Korea. *Clin Mol Hepatol* 2012; 18(4):391–396. doi:10.3350/cmh.2012.18.4.391
67. **Mohanty A, Kapuria D, Canakis A, et al.** Fresh frozen plasma transfusion in acute variceal haemorrhage: results from a multicentre cohort study. *Liver Int* 2021; 41(8):1901–1908. doi:10.1111/liv.14936
68. **European Association for the Study of the Liver.** EASL Clinical Practice Guidelines: vascular diseases of the liver. *J Hepatol* 2016; 64(1):179–202. doi:10.1016/j.jhep.2015.07.040
69. **Kumar M, Ahmad J, Maiwall R, et al.** Thromboelastography-guided blood component use in patients with cirrhosis with nonvariceal bleeding: a randomized controlled trial. *Hepatology* 2020; 71(1): 235–246. doi:10.1002/hep.30794

Address: Christina C. Lindenmeyer, MD, Department of Gastroenterology and Hepatology, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; lindenc@ccf.org